We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can BWX Technologies' Nuclear Medicine Expansion Boost Growth?
Read MoreHide Full Article
Key Takeaways
BWXT expands into nuclear medicine through Kinectrics' isotope production and supply capabilities.
BWXT's commercial operations span medical radioisotopes, radiopharmaceuticals and diagnostic imaging products.
BWXT broadens its healthcare reach through partnerships with life science and pharmaceutical companies.
BWX Technologies, Inc. (BWXT - Free Report) is broadening its commercial nuclear portfolio through expanded capabilities in nuclear medicine and medical radioisotopes. The company's acquisition of Kinectrics in May 2025 added capabilities in the production and supply of isotopes for the radiopharmaceutical industry, enabling BWXT to expand its presence across both nuclear power and nuclear medicine markets.
BWX Technologies’ commercial operations segment already provides products for diagnostic imaging and radiotherapeutic treatments, including medical radioisotopes, radiopharmaceuticals and medical devices. These capabilities give the company exposure to healthcare applications that rely on specialized nuclear materials and technologies.
The Kinectrics acquisition also strengthens BWX Technologies’ ability to serve customers across the nuclear medicine value chain. Kinectrics has capabilities spanning isotope production and supply, while BWX Technologies’ existing commercial operations include partnerships with life science and pharmaceutical companies. This combination expands the company's commercial reach beyond traditional nuclear energy applications.
Demand for critical medical radioisotopes and radiopharmaceuticals provides another avenue for BWX Technologies to leverage its nuclear expertise. As the company integrates Kinectrics' capabilities, its broader presence across nuclear medicine could diversify its commercial operations while creating opportunities in specialized healthcare markets.
Companies Expanding Nuclear Medicine Capabilities
The nuclear medicine industry continues advancing radiopharmaceutical and diagnostic imaging capabilities to support growing demand for specialized medical applications. Companies like Cardinal Health, Inc. (CAH - Free Report) and GE HealthCare Technologies Inc. (GEHC - Free Report) are also expanding their presence across the nuclear medicine and medical imaging markets.
Cardinal Health operates nuclear pharmacies and radiopharmaceutical manufacturing facilities, supporting the preparation, production and distribution of products used in nuclear medicine.
GE HealthCare provides medical imaging and diagnostic pharmaceutical technologies that support nuclear medicine workflows and broader diagnostic applications.
Earnings Estimates for BWXT Stock
The Zacks Consensus Estimate for 2026 and 2027 earnings per share suggests year-over-year growth of 18.45% and 10.52%, respectively.
Image Source: Zacks Investment Research
BWXT Stock Trading at a Discount
BWX Technologies is trading at a discount relative to the industry, with a forward 12-month price-to-sales of 3.94X compared with the industry average of 8.65X.
Image Source: Zacks Investment Research
BWXT Stock Price Performance
Over the past year, BWXT shares have fallen 1.2% against the industry’s 13.9% growth.
View the Zacks #1 Rank List
Image: Bigstock
Can BWX Technologies' Nuclear Medicine Expansion Boost Growth?
Key Takeaways
BWX Technologies, Inc. (BWXT - Free Report) is broadening its commercial nuclear portfolio through expanded capabilities in nuclear medicine and medical radioisotopes. The company's acquisition of Kinectrics in May 2025 added capabilities in the production and supply of isotopes for the radiopharmaceutical industry, enabling BWXT to expand its presence across both nuclear power and nuclear medicine markets.
BWX Technologies’ commercial operations segment already provides products for diagnostic imaging and radiotherapeutic treatments, including medical radioisotopes, radiopharmaceuticals and medical devices. These capabilities give the company exposure to healthcare applications that rely on specialized nuclear materials and technologies.
The Kinectrics acquisition also strengthens BWX Technologies’ ability to serve customers across the nuclear medicine value chain. Kinectrics has capabilities spanning isotope production and supply, while BWX Technologies’ existing commercial operations include partnerships with life science and pharmaceutical companies. This combination expands the company's commercial reach beyond traditional nuclear energy applications.
Demand for critical medical radioisotopes and radiopharmaceuticals provides another avenue for BWX Technologies to leverage its nuclear expertise. As the company integrates Kinectrics' capabilities, its broader presence across nuclear medicine could diversify its commercial operations while creating opportunities in specialized healthcare markets.
Companies Expanding Nuclear Medicine Capabilities
The nuclear medicine industry continues advancing radiopharmaceutical and diagnostic imaging capabilities to support growing demand for specialized medical applications. Companies like Cardinal Health, Inc. (CAH - Free Report) and GE HealthCare Technologies Inc. (GEHC - Free Report) are also expanding their presence across the nuclear medicine and medical imaging markets.
Cardinal Health operates nuclear pharmacies and radiopharmaceutical manufacturing facilities, supporting the preparation, production and distribution of products used in nuclear medicine.
GE HealthCare provides medical imaging and diagnostic pharmaceutical technologies that support nuclear medicine workflows and broader diagnostic applications.
Earnings Estimates for BWXT Stock
The Zacks Consensus Estimate for 2026 and 2027 earnings per share suggests year-over-year growth of 18.45% and 10.52%, respectively.
Image Source: Zacks Investment Research
BWXT Stock Trading at a Discount
BWX Technologies is trading at a discount relative to the industry, with a forward 12-month price-to-sales of 3.94X compared with the industry average of 8.65X.
Image Source: Zacks Investment Research
BWXT Stock Price Performance
Over the past year, BWXT shares have fallen 1.2% against the industry’s 13.9% growth.
Image Source: Zacks Investment Research
BWXT’s Zacks Rank
BWX Technologies currently sports a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.